FOLH1 and pachyonychia congenita: Up to 800 MBq highly pure (>98%) 68Ga-DKFZ-PSMA-11 was provided for patient administration within 20–30 min, and the localization of primary PC and lymph node involvement, as well as advanced metastatic PC scenarios, seemed not to be compromised by the kit-manufacturing protocol.